Research programme: sexual dysfunction therapy - OptiNose
Alternative Names: Sexual dysfunction therapy research programme - OptiNoseLatest Information Update: 04 Nov 2017
At a glance
- Originator OptiNose AS
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Male sexual dysfunction
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Male-sexual-dysfunction in Norway (Intranasal, Spray)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Male-sexual-dysfunction in United Kingdom (Intranasal, Spray)
- 08 Mar 2006 This programme is still in active development - (BPN-2006)